Pharmacokinetic Study of Arformoterol Tartrate in Rat Lungs / 中国药学杂志

ABSTRACT

OBJECTIVE: To establish an LC-MS/MS method for the determination of arformoterol tartrate in rat lungs and study the pharmacokinetics of arformoterol tartrate in rat lungs. METHODS: Lung samples were collected at different time points after SD rats were given nebulized infusion solution of arformoterol tartrate. An LC-MS/MS method was established and validated to analyze the drug concentrations,and pharmacokinetic parameters were calculated by professional software named DAS3.0 pharmacokinetic program. RESULTS: The main pharmacokinetic parameters of arformoterol tartrate in the lungs of rats were as follows t1/2 was 15.55 h, cmax was 16.48 ng•g-1, AUC0-t was 48.41 ng•h•g-1, and MRT0-t was 5.45 h. CONCLUSION: After aerosolization of arformoterol tartrate inhalation solution, the drugis rapidly distributed in the lung, has a long half-life and can be maintained for a certain period of time, suggesting that atomized administration of arformoterol tartrate can be used for the treatment of chronic obstructive pulmonary disease.